At http://www.qualitystocks.net/ you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.
We would like to highlight AtheroGenics Inc. (NASDAQ: AGIX). The company is a research-based pharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease. It has one late stage clinical drug development program. AGI-1067 is the Company’s investigational oral drug with demonstrated anti-inflammatory and antioxidant properties that is being studied to determine its ability to improve glycemic control (blood sugar levels) in patients with diabetes and potentially reduce clinical events in patients with coronary heart disease.
In the company’s recent news,
AtheroGenics Inc. announced top-line results from its ANDES phase 3 clinical trial of AGI-1067, the company’s lead antioxidant and anti-inflammatory drug candidate for the treatment of type 2 diabetes. According to the trial study, AGI-1067 met the primary efficacy endpoint for the reduction in glycosylated hemoglobin in both 75mg and 150mg doses. Russell M. Medford, M.D., Ph.D., president and CEO of AtheroGenics said the company is pleased with the results, which will allow the company to progress with AGI-1067’s development.
“We believe that AGI-1067, through its unique mechanism of action, could become the first diabetes treatment with demonstrated cardiovascular safety, and with the potential to reduce cardiovascular hard events including cardiovascular death, heart attack and stroke, as reported from the 6,144 patient phase 3 ARISE trial, which concluded in 2007,” Medford stated in the press release.
The company also announced it has developed a patient identification tool that will allow medical personnel to screen for the small number of patients who may run the risk of hepatic effects that have been observed during treatment with AGI-1067. According to the press release, the tool has performed well at identifying at-risk diabetes patients across all doses used in the ARISE and ANDES trials.
“We are excited about the advances we have made to date with the patient identification tool for AGI-1067,” Alexander Fleming, M.D., acting chief medical officer stated. “We plan to incorporate this tool into the next AGI-1067 phase 3 trial.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
